

CSF3R Gln776X and ASXL1 mutations in multiple myeloma associated with chronic neutrophilic leukemia: case report and literature review

Ying Han, Yajun Shi, Tao Wu*, Jinmao Zhou*

940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou, China

Submitted: 26 October 2024; **Accepted:** 25 December 2024

Online publication: 31 December 2024

Arch Med Sci 2024; 20 (6): 2090–2093

DOI: <https://doi.org/10.5114/aoms/199530>

Copyright © 2024 Termedia & Banach

***Corresponding authors:**

Tao Wu, Jinmao Zhou
940th Hospital of
Joint Logistics Support
Force of Chinese
People's Liberation Army
Lanzhou, China
E-mail: wutao6123@163.com

Multiple myeloma (MM) is a malignant clonal disorder of plasma cells, for which no cure has been found. Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative tumor first described in 1920 [1]. The World Health Organization (WHO) officially named and classified CNL in 2001 and revised its diagnostic criteria in 2008 [2–4]. The coexistence of MM and CNL is exceptionally rare, complicating the clinical diagnosis and frequently leading to misdiagnosis or underdiagnosis. In our hematology department, we managed a case of MM and CNL in a patient with CSF3R (Gln776X) and ASXL1 mutations. Given the scarcity of reported cases, this study aims to discuss the diagnosis, treatment, and pathogenesis of this rare condition, combining our findings with relevant literature.

On April 23, 2019, an 86-year-old male patient diagnosed with MM and CNL was admitted. The patient presented with a “pulmonary infection accompanied by pleural effusion”. During anti-infective therapy, there was a persistent abnormal elevation in white blood cell count. Hematologic examination revealed a white blood cell count of $67.90 \times 10^9/l$, predominantly mature neutrophils ($64.31 \times 10^9/l$) (Figures 1, 2). Biochemical analysis indicated an elevated globulin level of 41.7 g/l. Immunoglobulin analysis showed an IgA level of 3640.0 mg/dl. Serum immunofixation electrophoresis revealed positive results for IgA and λ light chain. Free light chain assay indicated λ at 1790 mg/l in blood and 9610 mg/l in urine. Peripheral blood cell classification showed 92% segmented neutrophils and 8% mature lymphocytes. The neutrophil alkaline phosphatase score was 226. Bone marrow cytology revealed marked hyperplasia with a predominance of granulopoiesis (78.8%), including mature neutrophils, myelocytes, metamyelocytes, and segmented neutrophils. Plasma cells constituted 12%, with 3.2% being immature and pro-plasma cells, and bi-nucleated and multi-nucleated plasma cells were observed. Flow cytometry demonstrated approximately 0.75% monoclonal plasma cells. The MM prognosis fluorescence *in situ* hybridization (FISH) panel showed negativity for P53, RB1, 1q21, D13S319, and IGH. A comprehensive myeloproliferative neoplasm (MPN) gene panel revealed negativity for BCR/ABL, JAK2, CALR, and MPL. AML/MDS/MPN targeted gene sequencing identified positive mutations in CSF3R (Gln776X) and ASXL1. Chromosomal karyotyping revealed a normal male karyotype of 46, XY. PET-CT imaging demonstrated diffuse abnormal elevation in FDG metabolism along the axial skeleton. The diagnosis of MM and CNL (CSF3R




Figure 1. Mature granulocytes and plasma cells (Wright-Giemsa stain, $\times 1000$)




Figure 2. Tumor-like plasma cells (Wright-Giemsa stain, $\times 1000$)

(Gln776X) with ASXL1 mutation) was confirmed. The procedures in this study adhered to the 2013 revised Declaration of Helsinki. Informed consent was obtained from the patient's family, and they signed a clinical research consent form.

During hospitalization, the patient underwent various laboratory and auxiliary examinations. These included CT, CBC, peripheral blood cell morphology, NAP score, bone marrow smear, immunoglobulin measurement, serum protein electrophoresis, immunofixation electrophoresis, blood and urine free light chain assay, coagulation function and biochemical parameters, bone marrow flow cytometry, MM prognosis FISH panel, MPN gene panel, AML/MDS/MPN mutational gene sequencing, chromosomal karyotyping, and PET-CT. These examinations provided a comprehensive profile of the patient's health status, aiding in diagnostic and prognostic evaluation.

MM diagnosis requires at least one of the following criteria to be met in addition to the initial two: 1) clonal plasma cells $\geq 10\%$ in bone marrow or tissue biopsy confirmation of a plasma cell tumor; 2) presence of M protein in serum or urine; 3) abnormal target organ function or bone marrow tumor indicators: a) target organ damage (CRAB symptoms); b) no target organ damage but presence of SLiM symptoms. Treatment for MM typically involves proteasome inhibitors, immunomodulatory agents, and dexamethasone, followed by autologous hematopoietic stem cell transplantation (ASCT) post-induction remission [5].

CNL diagnostic criteria, revised by the WHO in 2016 [6], include: 1) peripheral blood white cell count $\geq 25 \times 10^9/l$, with neutrophilic bands and segmented nuclei $\geq 80\%$, and rare promyelocytes, myelocytes, and metamyelocytes; 2) increased bone marrow activity with elevated neutrophil count and normal maturation, less than 5% primitive granulocytes; 3) exclusion of BCR/ABL-positive chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET),

or chronic idiopathic myelofibrosis (CIMF); 4) absence of PDGFR α , PDGFR β , FGFR1, or PCM1-JAK2 rearrangements; 5) presence of CSF3R T618I or other activating CSF3R mutations. Treatment includes allo-HSCT, cytoreductive therapy, and targeted drugs such as ruxolitinib, though there is no standardized treatment, and prognosis remains poor, with a median survival of approximately 2 years [7].

The patient presented with a "pulmonary infection with pleural effusion". CT scans indicated bilateral lung infections with pleural effusion. The patient did not have fever, bone pain, or mucocutaneous bleeding. Treatment included antimicrobial therapy and closed thoracic drainage for pleural effusion. The patient had a history of diabetes for over 20 years, managed with insulin, and irregular blood glucose monitoring. There was no significant family history.

Initial blood examination showed a white blood cell count (WBC) of $67.90 \times 10^9/l$, with a neutrophil count of $64.31 \times 10^9/l$ and a neutrophil percentage of 95.4%. Other values included hemoglobin (HGB) at 119 g/l and platelet count of $188 \times 10^9/l$. Biochemical analysis showed uric acid at 737.0 $\mu\text{mol/l}$, creatinine at 98.0 $\mu\text{mol/l}$, urea at 10.10 mmol/l, glycosylated serum protein at 5.5 mmol/l, β_2 -microglobulin at 8.84 mg/l, globulin at 41.7 g/l, and albumin at 29.1 g/l. Immunoglobulin analysis indicated an IgA level of 3640.0 mg/dl (normal: 82–453 mg/dl). Serum immunofixation electrophoresis was positive for both IgA and λ light chains. Free light chain assay revealed κ at 18.2 mg/l (normal: 6.7–22.4 mg/l), λ at 1790 mg/l (normal: 8.3–27.0 mg/l), and a κ/λ ratio of 0.010 (normal: 0.31–1.56). Urine free light chain analysis showed κ at 140 mg/l (normal: 0–25.8 mg/l), λ at 9610 mg/l (normal: 0–11.3 mg/l), and a κ/λ ratio of 0.015. Peripheral blood cell classification indicated 92% segmented neutrophils and 8% mature lymphocytes. The neutrophil alkaline phosphatase (NAP) score was 226. Bone marrow

cytology showed significant myeloid cell proliferation (78.8%), mainly mature neutrophils, myelocytes, metamyelocytes, and segmented neutrophils. The percentage of red blood cells was 2%, mature lymphocytes 7.2%, and plasma cells 12%, including 3.2% immature and pro-plasma cells, with bi-nucleated and multi-nucleated plasma cells observed. Flow cytometry indicated approximately 0.75% monoclonal plasma cells, positive for CD38, CD138, cλ, and negative for CD56, CD19, and κκ. FISH panel was negative for P53, RB1, 1q21, D13S319, and IGH. MPN gene panel screening was negative for BCR/ABL, JAK2, CALR, and MPL. AML/MDS/MPN mutational gene sequencing showed positive mutations in CSF3R (Gln776X) and ASXL1. Chromosomal karyotyping was normal (46, XY). PET-CT imaging showed diffuse abnormal elevation in FDG metabolism along the axial skeleton.

Based on the clinical presentation and laboratory findings, the patient was diagnosed with: 1) multiple myeloma (smoldering type, IgA-λ light chain subtype) and 2) chronic neutrophilic leukemia (CNL). The patient's family declined treatment. Follow-up revealed that the patient survived for 4 months after discharge.

Approximately 20% of CNL patients have underlying tumors, often MM [8–11]. Clinical manifestations include hepatosplenomegaly and mucocutaneous or gastrointestinal bleeding in 25–30% of patients [8–11]. Many diagnosed patients lack specific clinical symptoms, leading to frequent underdiagnosis. The coexistence of MM and CNL is even rarer, complicating diagnosis and often resulting in misdiagnosis. Including CSF3R mutations in diagnostic criteria has provided specific markers, reducing misdiagnosis rates.

In the present case, the patient exhibited persistent leukocytosis after recovering from a pulmonary infection. Further tests, including MPN comprehensive gene screening and myeloid tumor second-generation sequencing, revealed CSF3R Gln776X and ASXL1 mutations. According to the latest WHO criteria, this confirmed diagnoses of smoldering multiple myeloma (SMM) and CNL. Apart from elevated white blood cell counts, other cell lines were normal at diagnosis. Clinical presentations varied, with some patients asymptomatic at diagnosis, and the time from onset to final diagnosis ranged from several months to years. Therefore, CSF3R mutation testing is crucial in diagnosing MM patients with persistent leukocytosis, especially when antimicrobial therapy is ineffective. CSF3R, a transmembrane receptor binding with G-CSF, plays a crucial role in granulocyte proliferation and differentiation [12]. The discovery of CSF3R mutations has advanced CNL research, with an 80–100% positivity rate in CNL cases [8, 13–15].

CNL patients typically have a median survival of around 2 years, with poor prognosis [11, 13, 16]. Diagnosed WBC levels $\geq 50 \times 10^9/l$ and ASXL1 mutations are adverse prognostic factors [9, 14]. Our patient, with CSF3R Gln776X and ASXL1 mutations, had a WBC count $\geq 50 \times 10^9/l$ and died after 4 months without treatment, suggesting these as potential adverse factors for MM combined with CNL.

Given the rarity of MM with CNL, no standardized treatment exists. MM is primarily treated with proteasome inhibitors, immunomodulatory agents, and dexamethasone, followed by autologous stem cell transplantation (ASCT) [5]. Traditional treatments such as hydroxyurea and interferon are effective for CNL but limited during progression. The age characteristics of CNL limit allo-HSCT's clinical application. Ruxolitinib has shown clinical improvement in some cases, but its efficacy remains inconsistent [8, 17–20]. For MM with CNL, treatment with a myeloma regimen achieved disease control, suggesting its effectiveness for CNL [8, 21]. Future research should focus on the molecular mechanisms and clinical applications of JAK inhibitors, SRC kinase inhibitors, and demethylating agents in treating CNL.

In conclusion, MM and CNL patients with CSF3R Q776X and ASXL1 mutations are rare. Treatment approaches for MM may manage this disease type effectively, but the effectiveness of JAK inhibitors, SRC kinase inhibitors, and demethylating agents warrants further research and confirmation.

Funding

Gansu Province Innovation Base and Talent Plan (Gansu Province Leukemia Clinical Medical Research Center) (No. 21JR7RA015).

Ethical approval

Not applicable.

Conflict of interest

The authors declare no conflict of interest.

References

1. Tuohy EL. A case of splenomegaly with polymorphonuclear neutrophil hyperleukocytosis. *Am J Med Sci* 1920; 160: 18-24.
2. Li B, Gale RP, Xiao Z. Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia. *J Hematol Oncol* 2014; 7: 93.
3. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. *Cancer* 2009; 115: 3842-7.
4. Vardiman JW, Brunning RD, Harris NL. WHO histological classification of chronic myeloproliferative diseases. 2001.

5. Kumar SK, Callander NS, Adekola K, et al. Multiple myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2023; 21: 1281-301.
6. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* 2016; 127: 2391-405.
7. Dao KT, Tyner JW, Gotlib J. Recent progress in chronic neutrophilic leukemia and atypical chronic myeloid leukemia. *Curr Hematol Malig Rep* 2017; 12: 432-41.
8. Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. *N Engl J Med* 2013; 368: 1781-90.
9. Elliott MA, Pardanani A, Hanson CA, et al. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. *Am J Hematol* 2015; 90: 653-6.
10. Böhm J, Kock S, Schaefer HE, Fisch P. Evidence of clonality in chronic neutrophilic leukaemia. *J Clin Pathol* 2003; 56: 292-5.
11. Elliott MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. *Leukemia* 2005; 19: 313-7.
12. Metcalf D. The granulocyte-macrophage colony-stimulating factors. *Science* 1985; 229: 16-22.
13. Pardanani A, Lasho TL, Laborde RR, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. *Leukemia* 2013; 27: 1870-3.
14. Guo YJ, Wang Y, Wang LH, et al. Analysis of clinical features and prognosis of patients with chronic neutrophilic leukemia. *Zhongguo Shi Yan Xue Ye Xue Za Zhi* 2020; 28: 82-7.
15. Ouyang Y, Qiao C, Chen Y, Zhang SJ. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia. *Oncotarget* 2017; 8: 20834-41.
16. Szuber N, Finke CM, Lasho TL, et al. CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. *Blood Cancer J* 2018; 8: 21.
17. Fleischman AG, Maxson JE, Luty SB, et al. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. *Blood* 2013; 122: 3628-31.
18. Lasho TL, Mims A, Elliott MA, Finke C, Pardanani A, Tefferi A. Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib. *Leukemia* 2014; 28: 1363-5.
19. Wu XB, Wu WW, Zhou Y, Wang X, Li J, Yu Y. Coexisting of bone marrow fibrosis, dysplasia and an X chromosomal abnormality in chronic neutrophilic leukemia with CSF3R mutation: a case report and literature review. *BMC Cancer* 2018; 18: 343.
20. Guastafierro V, Ubezio M, Manes N, Milanese C, Della Porta M, Bonometti A. CSF3R-mutant chronic myelomonocytic leukemia is a distinct clinically subset with abysmal prognosis: a case report and systematic review of the literature. *Leuk Lymphoma* 2023; 64: 1566-73.
21. Shi J, Ni Y, Li J, Qiu H, Miao K. Concurrent chronic neutrophilic leukemia blast crisis and multiple myeloma: a case report and literature review. *Oncol Lett* 2015; 9: 2208-10.